文献速递肾移植

肾移植维持免疫抑制试验不良事件报告完整性:系统综述

Completeness of reporting of adverse events in trials of maintenance immunosuppression in kidney transplantation: a systematic review.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

该系统综述评估肾移植维持免疫抑制随机对照试验中不良事件(AE)的报告质量,共纳入233项试验。仅69%报告至少一种AE,定义、方法学和严重程度报告率分别为10%、8%和17%。AE报告频率未反映已知药物副作用谱,且与产业资助、多中心和随访时间短相关。

要点

  • 肾移植免疫抑制试验中AE报告不完整且选择性,仅10%提供定义。
  • 钙调神经磷酸酶抑制剂试验中震颤报告率仅22%,精神症状缺如。
  • 产业资助、多中心及随访<24个月的试验更可能报告AE。

核心结论

  • 肾移植免疫抑制试验中AE存在选择性报告,可能不可靠用于临床决策。
  • 建议强制遵循CONSORT harms扩展声明以确保AE报告透明。

研究设计与样本

  • 共纳入233项试验,采用CONSORT harms扩展声明23项条目进行评价。

主要发现

  • 233项试验中163项(69%)报告至少一种AE。
  • 仅17项(10%)提供AE定义或合理性,13项(8%)描述方法,27项(17%)测量严重程度。
  • 90项钙调神经磷酸酶抑制剂试验中,22%报告震颤,3%报告感觉异常,无报告焦虑、攻击或情绪波动。
  • 报告至少一种AE的试验更可能为产业资助[校正OR 7.6(95%CI 3.4-17.1)]、多中心[OR 5.9(95%CI 1.7-18.7)]和随访时间<24个月[OR 3.7(95%CI 1.4-10.2)]。

临床怎么用

  • 临床决策时应谨慎对待肾移植免疫抑制试验中的AE数据,注意选择性报告偏倚。
  • 解读AE数据时需考虑产业资助、多中心和随访时间短等因素的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Decision-making regarding immunosuppression after transplantation relies on robust evidence on the benefits and harms of available drugs. We aimed to evaluate the reporting of adverse events (AEs) in trials of maintenance immunosuppression in kidney transplantation. METHODS: We conducted a systematic review of published randomized controlled trials of maintenance immunosuppression following kidney transplantation in the Cochrane Kidney and Transplant Register (January 2003-December 2015). Appraisal against the 23-item harms extension of the Consolidated Standards of Reporting Trials statement was conducted. RESULTS: Of 233 trials, 163 (69%) reported at least one AE. Only 17 (10%) provided definitions or justified the AEs, 13 (8%) described methods and 27 (17%) measured severity. Forty AE types were reported, with gastrointestinal being the most common [116 (71%)]. The frequency of reporting did not reflect known drug side-effect profiles. For example, of 90 calcineurin inhibitor trials, only 22% reported tremors, 3% paresthesia and none anxiety, aggression or mood swings. Trials that reported at least one adverse effect were more likely to be industry funded {adjusted odds ratio [OR] 7.6 [95% confidence interval (CI) 3.4-17.1]}, multicenter [OR 5.9 (95% CI 1.7-18.7)] and with follow-up time <24 months [OR 3.7 (95% CI 1.4-10.2)]. CONCLUSIONS: AEs in kidney transplant immunosuppression trials appear to be selectively reported and may be unreliable for clinical decisions. Adherence to the Consolidated Standards of Reporting Trials harms extension should be mandatory to ensure transparent reporting of AEs that are important to patients and clinicians.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Howell M, Yeo R, Tong A, et al. Completeness of reporting of adverse events in trials of maintenance immunosuppression in kidney transplantation: a systematic review. Nephrol Dial Transplant. 2017. PMID: 29059401. doi:10.1093/ndt/gfx216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。